Liposomal Nanosystems in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease that affects the joints and results in reduced patient quality of life due to its chronic nature and several comorbidities. RA is also associated with a high socioeconomic burden. Currently, several available therapies minimize symptoms and prevent...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/4/454 |
| _version_ | 1797539826434572288 |
|---|---|
| author | Margarida Ferreira-Silva Catarina Faria-Silva Pedro Viana Baptista Eduarda Fernandes Alexandra Ramos Fernandes Maria Luísa Corvo |
| author_facet | Margarida Ferreira-Silva Catarina Faria-Silva Pedro Viana Baptista Eduarda Fernandes Alexandra Ramos Fernandes Maria Luísa Corvo |
| author_sort | Margarida Ferreira-Silva |
| collection | DOAJ |
| description | Rheumatoid arthritis (RA) is an autoimmune disease that affects the joints and results in reduced patient quality of life due to its chronic nature and several comorbidities. RA is also associated with a high socioeconomic burden. Currently, several available therapies minimize symptoms and prevent disease progression. However, more effective treatments are needed due to current therapies’ severe side-effects, especially under long-term use. Drug delivery systems have demonstrated their clinical importance—with several nanocarriers present in the market—due to their capacity to improve therapeutic drug index, for instance, by enabling passive or active targeting. The first to achieve market authorization were liposomes that still represent a considerable part of approved delivery systems. In this manuscript, we review the role of liposomes in RA treatment, address preclinical studies and clinical trials, and discuss factors that could hamper a successful clinical translation. We also suggest some alterations that could potentially improve their progression to the market. |
| first_indexed | 2024-03-10T12:51:23Z |
| format | Article |
| id | doaj.art-89c7603ff1244cd0a996580cb3c8b721 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T12:51:23Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-89c7603ff1244cd0a996580cb3c8b7212023-11-21T13:02:43ZengMDPI AGPharmaceutics1999-49232021-03-0113445410.3390/pharmaceutics13040454Liposomal Nanosystems in Rheumatoid ArthritisMargarida Ferreira-Silva0Catarina Faria-Silva1Pedro Viana Baptista2Eduarda Fernandes3Alexandra Ramos Fernandes4Maria Luísa Corvo5Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, PortugalInstituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, PortugalUnidade de Ciências Biomoleculares Aplicadas UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Campus de Caparica, 2829-516 Caparica, PortugalAssociated Laboratory for Green Chemistry of the Network of Chemistry and Technology (LAQV, REQUIMTE), Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, PortugalUnidade de Ciências Biomoleculares Aplicadas UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Campus de Caparica, 2829-516 Caparica, PortugalInstituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, PortugalRheumatoid arthritis (RA) is an autoimmune disease that affects the joints and results in reduced patient quality of life due to its chronic nature and several comorbidities. RA is also associated with a high socioeconomic burden. Currently, several available therapies minimize symptoms and prevent disease progression. However, more effective treatments are needed due to current therapies’ severe side-effects, especially under long-term use. Drug delivery systems have demonstrated their clinical importance—with several nanocarriers present in the market—due to their capacity to improve therapeutic drug index, for instance, by enabling passive or active targeting. The first to achieve market authorization were liposomes that still represent a considerable part of approved delivery systems. In this manuscript, we review the role of liposomes in RA treatment, address preclinical studies and clinical trials, and discuss factors that could hamper a successful clinical translation. We also suggest some alterations that could potentially improve their progression to the market.https://www.mdpi.com/1999-4923/13/4/454rheumatoid arthritisdrug delivery nanosystemsliposomespassive targetingactive targeting |
| spellingShingle | Margarida Ferreira-Silva Catarina Faria-Silva Pedro Viana Baptista Eduarda Fernandes Alexandra Ramos Fernandes Maria Luísa Corvo Liposomal Nanosystems in Rheumatoid Arthritis Pharmaceutics rheumatoid arthritis drug delivery nanosystems liposomes passive targeting active targeting |
| title | Liposomal Nanosystems in Rheumatoid Arthritis |
| title_full | Liposomal Nanosystems in Rheumatoid Arthritis |
| title_fullStr | Liposomal Nanosystems in Rheumatoid Arthritis |
| title_full_unstemmed | Liposomal Nanosystems in Rheumatoid Arthritis |
| title_short | Liposomal Nanosystems in Rheumatoid Arthritis |
| title_sort | liposomal nanosystems in rheumatoid arthritis |
| topic | rheumatoid arthritis drug delivery nanosystems liposomes passive targeting active targeting |
| url | https://www.mdpi.com/1999-4923/13/4/454 |
| work_keys_str_mv | AT margaridaferreirasilva liposomalnanosystemsinrheumatoidarthritis AT catarinafariasilva liposomalnanosystemsinrheumatoidarthritis AT pedrovianabaptista liposomalnanosystemsinrheumatoidarthritis AT eduardafernandes liposomalnanosystemsinrheumatoidarthritis AT alexandraramosfernandes liposomalnanosystemsinrheumatoidarthritis AT marialuisacorvo liposomalnanosystemsinrheumatoidarthritis |